Puyuan Xing

20PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.

Lige Wu, Zihua Zou, Yan Li

|Feb 09, 2026
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China.

Lige Wu, Jiayu Liu, Zihua Zou

|Jun 03, 2025
DNAJA: emerging targets for anti-tumor therapy.

Lige Wu, Puyuan Xing, Junling Li

|May 12, 2025
A Real-World Study: Therapeutic Outcomes of ROS1-Positive Advanced NSCLC.

Hanqi Yuan, Zihua Zou, Xuezhi Hao

|May 11, 2025
Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study.

Puyuan Xing, Xingxiang Pu, Yu Zhou

|Jan 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Zihua Zou, Lige Wu, Xuezhi Hao

Pageof 4

Frequent Collaborators

14 joint publications

Junling Li

6 joint publications

Zihua Zou

4 joint publications

Lige Wu

4 joint publications

Yan Wang